| ID | Sequence | Length | GC content |
|---|---|---|---|
| AUUACUGUUGGAGCUACAGGGAGAGAAACAGAGGAGGAGACUGCAAGAG… | 2856 nt | 0.4622 | |
| AUUACUGUUGGAGCUACAGGGAGAGAAACAGAGGAGGAGACUGCAAGAG… | 6456 nt | 0.4306 | |
| AGUUGAAAACAAUGCAAACGCAGAGCGUCGUGCCUGGGGCGCAGCGGCC… | 6599 nt | 0.4428 | |
| GACAGCGCGGCCCGGGAACGGCGUCGAGGUCCAGGCGGUCCCCCUGCCC… | 6794 nt | 0.4413 | |
| AUUACUGUUGGAGCUACAGGGAGAGAAACAGAGGAGGAGACUGCAAGAG… | 6378 nt | 0.4291 |
This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers. [provided by RefSeq, Mar 2012] CIViC Summary for PDGFRA Gene Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.
A study in humans demonstrated that the PDGFRA is a protein marker used to identify fibroblasts (FBs) in the corpus cavernosum, with its expression defining the FB cluster and its downregulation observed in circulating T cells during the injury stage following major trauma compared to the recovery stage [Zhao et al. DOI:10.1038/s41467-022-31950-9][Rau et al. DOI:10.2147/JIR.S375881].